durvalumab

8 · 20 / page

Ask MedXY AI

Latest news

Tag

GastroenterologyBiliary tract cancercisplatin

Durvalumab Plus Chemotherapy Extends Survival in Advanced Biliary Tract Cancer: Insights from the TOPAZ-1 Trial Four-Year Post Hoc Analysis

By MedXY|Jul 12, 2026

A four-year post hoc analysis of the TOPAZ-1 trial confirms that durvalumab combined with gemcitabine and cisplatin offers a long-term survival benefit with manageable safety as first-line treatment for advanced biliary tract cancer.

Starting Durvalumab with Chemoradiotherapy in Unresectable Stage III NSCLC Did Not Improve Outcomes: PACIFIC-2 Recalibrates the Timing of Immunotherapy

newschemoradiotherapy

durvalumab

Latest news

Durvalumab Plus Chemotherapy Extends Survival in Advanced Biliary Tract Cancer: Insights from the TOPAZ-1 Trial Four-Year Post Hoc Analysis

Starting Durvalumab with Chemoradiotherapy in Unresectable Stage III NSCLC Did Not Improve Outcomes: PACIFIC-2 Recalibrates the Timing of Immunotherapy

Checkpoint inhibition for frail patients: Durvalumab with carboplatin–etoposide shows tolerability and a 1‑year survival signal in poor‑performance‑status extensive‑stage SCLC (NEJ045A)

Durvalumab Combined with BCG for High-Risk, BCG-Naive Non-Muscle-Invasive Bladder Cancer: Final Phase 3 Trial Results from POTOMAC Study

Comparative Effectiveness and Safety of PD-L1 Inhibitors with Chemotherapy in Extensive-Stage Small Cell Lung Cancer: Insights from a French Nationwide Cohort Study

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A 3-Year Survival Update from the Phase III TOPAZ-1 Study

Five-Year Survival Outcomes Confirm STRIDE’s Breakthrough in Unresectable Hepatocellular Carcinoma

Perioperative Durvalumab Plus FLOT Improves Event-Free Survival in Resectable Gastric and Gastroesophageal Junction Cancer: Results from the MATTERHORN Trial